{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T08:15:05Z","timestamp":1742976905354,"version":"3.40.3"},"publisher-location":"Cham","reference-count":18,"publisher":"Springer Nature Switzerland","isbn-type":[{"type":"print","value":"9783031646355"},{"type":"electronic","value":"9783031646362"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-3-031-64636-2_21","type":"book-chapter","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T06:02:27Z","timestamp":1724738547000},"page":"278-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing MET Copy Number Estimation by Factoring in Tumor Purity and Variant Types"],"prefix":"10.1007","author":[{"given":"Minchao","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhili","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"3","key":"21_CR1","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3390\/cancers6031540","volume":"6","author":"H Kawakami","year":"2014","unstructured":"Kawakami, H., Okamoto, I., Okamoto, W., Tanizaki, J., Nakagawa, K., Nishio, K.: Targeting MET amplification as a new oncogenic driver. Cancers 6(3), 1540\u20131552 (2014)","journal-title":"Cancers"},{"issue":"9","key":"21_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","volume":"17","author":"R Guo","year":"2020","unstructured":"Guo, R., Luo, J., Chang, J., Rekhtman, N., Arcila, M., Drilon, A.: MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat. Rev. Clin. Oncol. 17(9), 569\u2013587 (2020)","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"21_CR3","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge, D.R., et al.: Crizotinib in patients with MET-Amplified NSCLC. J. Thorac. Oncol. 16(6), 1017\u20131029 (2021)","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"21_CR4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf, J., et al.: Capmatinib in MET Exon 14-mutated or MET-amplified non-small-cell lung cancer. N. Engl. J. Med. 383(10), 944\u2013957 (2020)","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"21_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.19.00033","volume":"37","author":"DR Camidge","year":"2019","unstructured":"Camidge, D.R., Davies, K.D.: MET copy number as a secondary driver of epidermal growth factor receptor tyrosine kinase inhibitor resistance in EGFR-mutant non-small-cell lung cancer. J. Clin. Oncol. 37(11), 855\u2013857 (2019)","journal-title":"J. Clin. Oncol."},{"key":"21_CR6","doi-asserted-by":"crossref","unstructured":"Westover, D., Zugazagoitia, J., Cho, B.C., Lovly, C.M., Paz-Ares, L., Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann. Oncol. 29(suppl_1), i10\u2013i19 (2018)","DOI":"10.1093\/annonc\/mdx703"},{"issue":"4","key":"21_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.cllc.2014.12.013","volume":"16","author":"A Matikas","year":"2015","unstructured":"Matikas, A., Mistriotis, D., Georgoulias, V., Kotsakis, A.: Current and future approaches in the management of non-small-cell lung cancer patients with resistance to EGFR TKIs. Clin. Lung Cancer 16(4), 252\u2013261 (2015)","journal-title":"Clin. Lung Cancer"},{"issue":"9","key":"21_CR8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., Tiseo, M.: Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer 121(9), 725\u2013737 (2019)","journal-title":"Br. J. Cancer"},{"issue":"11","key":"21_CR9","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1158\/1078-0432.CCR-19-3906","volume":"26","author":"I Dagogo-Jack","year":"2020","unstructured":"Dagogo-Jack, I., et al.: MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin. Cancer Res. 26(11), 2535\u20132545 (2020)","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"21_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","volume":"21","author":"LV Sequist","year":"2020","unstructured":"Sequist, L.V., et al.: Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 21(3), 373\u2013386 (2020)","journal-title":"Lancet Oncol."},{"issue":"31","key":"21_CR11","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","volume":"36","author":"YL Wu","year":"2018","unstructured":"Wu, Y.L., et al.: Phase Ib\/II study of Capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-Mutated, MET factor-dysregulated non-small-cell lung cancer. J. Clin. Oncol. 36(31), 3101\u20133109 (2018)","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"21_CR12","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","volume":"10","author":"G Recondo","year":"2020","unstructured":"Recondo, G., Che, J., J\u00e4nne, P.A., Awad, M.M.: Targeting MET dysregulation in cancer. Cancer Discov. 10(7), 922\u2013934 (2020)","journal-title":"Cancer Discov."},{"issue":"4","key":"21_CR13","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1158\/2767-9764.CRC-22-0438","volume":"3","author":"B Sun","year":"2023","unstructured":"Sun, B., et al.: Detection of MET Polysomy by next-generation sequencing and its clinical relevance for MET inhibitors. Cancer Res. Commun. 3(4), 532\u2013539 (2023)","journal-title":"Cancer Res. Commun."},{"issue":"1","key":"21_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","volume":"12","author":"A Drilon","year":"2017","unstructured":"Drilon, A., Cappuzzo, F., Ou, S.H.I., Camidge, D.R.: Targeting MET in lung cancer: will expectations finally be MET? J. Thorac. Oncol. 12(1), 15\u201326 (2017)","journal-title":"J. Thorac. Oncol."},{"key":"21_CR15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3389\/fgene.2020.00458","volume":"11","author":"X Yuan","year":"2020","unstructured":"Yuan, X., et al.: Accurate inference of tumor purity and absolute copy numbers from high-throughput sequencing data. Front. Genet. 11, 458 (2020)","journal-title":"Front. Genet."},{"issue":"5","key":"21_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S.L., et al.: Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30(5), 413\u2013421 (2012)","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"21_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/biostatistics\/kxh008","volume":"5","author":"AB Olshen","year":"2004","unstructured":"Olshen, A.B., Venkatraman, E.S., Lucito, R., Wigler, M.: Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5(4), 557\u2013572 (2004)","journal-title":"Biostatistics"},{"issue":"1","key":"21_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40164-021-00245-y","volume":"10","author":"LX Peng","year":"2021","unstructured":"Peng, L.X., et al.: MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors. Exp. Hematol. Oncol. 10(1), 52 (2021)","journal-title":"Exp. Hematol. Oncol."}],"container-title":["Lecture Notes in Computer Science","Bioinformatics and Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-64636-2_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T10:07:32Z","timestamp":1728986852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-64636-2_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031646355","9783031646362"],"references-count":18,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-64636-2_21","relation":{},"ISSN":["0302-9743","1611-3349"],"issn-type":[{"type":"print","value":"0302-9743"},{"type":"electronic","value":"1611-3349"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"28 August 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"Author M.C. and Z.C. are employed by Nanjing Geneseeq Technology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of Interests"}},{"value":"IWBBIO","order":1,"name":"conference_acronym","label":"Conference Acronym","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"International Work-Conference on Bioinformatics and Biomedical Engineering","order":2,"name":"conference_name","label":"Conference Name","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Gran Canaria","order":3,"name":"conference_city","label":"Conference City","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Spain","order":4,"name":"conference_country","label":"Conference Country","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"2024","order":5,"name":"conference_year","label":"Conference Year","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"15 July 2024","order":7,"name":"conference_start_date","label":"Conference Start Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"17 July 2024","order":8,"name":"conference_end_date","label":"Conference End Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"11","order":9,"name":"conference_number","label":"Conference Number","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"iwbbio2024","order":10,"name":"conference_id","label":"Conference ID","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"https:\/\/iwbbio.ugr.es\/","order":11,"name":"conference_url","label":"Conference URL","group":{"name":"ConferenceInfo","label":"Conference Information"}}]}}